الصفحة الرئيسية>>Signaling Pathways>> Others>> Carbonic Anhydrase>>hCAI/II-IN-6

hCAI/II-IN-6

رقم الكتالوجGC66029

hCAI / II-IN-6 هو مثبط للكربونيك الأنهيدراز البشري عن طريق الفم. يثبط hCAI / II-IN-6 بشكل انتقائي الأشكال الإسوية hCA II و hCA VII بقيم Ki تبلغ 220 و 4.9 و 6.5 و > 50000 نانومتر لـ hCA I و hCA II و hCA VII و hCA XII على التوالي. يُظهر hCAI / II-IN-6 نشاطًا مضادًا للاختلاج ونشاطًا مضادًا للصدمات الكهربائية القصوى (MES) في الجسم الحي. يمكن استخدام hCAI / II-IN-6 للبحث عن الصرع.

Products are for research use only. Not for human use. We do not sell to patients.

hCAI/II-IN-6 التركيب الكيميائي

Cas No.: 694466-00-7

الحجم السعر المخزون الكميّة
10mg
97٫20
متوفر
25mg
201٫60
متوفر
50mg
324٫00
متوفر
100mg
518٫40
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ??50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy[1].

hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities with Ki values of 220, 4.9, 6.5 and ??50000 nM, respectively[1].

hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo[1].
hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo[1].

Animal Model: Swiss albino mice[1]
Dosage: 30 and 100 mg/kg
Administration: Intraperitoneal injection; 30-100 mg/kg once
Result: Provided seizure attenuation and good anticonvulsant effect, and showed an ED50 of 13.7mg/kg in anticonvulsant quantification study.
Animal Model: Wistar albino rats[1]
Dosage: 30 mg/kg
Administration: Oral gavage; 30 mg/kg once
Result: Showed anti-MES activity and significant protection from seizures up to 1h of drug administration and action was gone reduced after 1h.

مراجعات

Review for hCAI/II-IN-6

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for hCAI/II-IN-6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.